Get the Stockscreener App
0.9677
2.41%
-0.0239
After Hours:
.97
0.0023
+0.24%
Oncolytics Biotech Inc stock is traded at $0.9677, with a volume of 642.31K.
It is down -2.41% in the last 24 hours and down -0.93% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.9916
Open:
$0.9971
24h Volume:
642.31K
Relative Volume:
0.86
Market Cap:
$104.13M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-3.6586
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
-1.63%
1M Performance:
-0.93%
6M Performance:
-19.36%
1Y Performance:
+11.49%
1-Day Range:
$0.96
$1.01
1-Week Range:
$0.9201
$1.01
52-Week Range:
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.9677 | 106.70M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Initiated | Lake Street | Buy |
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Oncolytics outlines strategic rationale for proposal to change jurisdiction - Yahoo Finance
Stocks in play: Oncolytics Biotech Inc. - Barchart.com
Oncolytics Biotech plans to shift incorporation from Canada to Nevada - Investing.com
Oncolytics (ONCY) Plans to Shift Incorporation to Nevada for Str - GuruFocus
Oncolytics Biotech plans to shift incorporation from Canada to Nevada By Investing.com - Investing.com South Africa
Oncolytics Biotech Seeks Nevada Domestication to Align with U.S. Growth Strategy - TipRanks
Oncolytics Biotech Inc. Proposes Change of Jurisdiction to Nevada to Enhance U.S. Focus and Strategic Growth - Quiver Quantitative
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada - GlobeNewswire
Oncolytics Biotech Inc. - Menafn.com
Is Oncolytics Biotech Inc. stock a contrarian buyInsider Buying & Technical Analysis for Trade Confirmation - ulpravda.ru
Oncolytics Biotech files patent application to extend pelareorep protection By Investing.com - Investing.com Australia
Is Oncolytics Biotech Inc. stock a buy for dividend growth - ulpravda.ru
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech - The Manila Times
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings - PharmiWeb.com
Oncolytics Biotech®? Provides Update on Intellectual Property Strategy and Patent Filings - MarketScreener
Why Oncolytics Biotech Inc. stock is rated strong buy2025 Valuation Update & Daily Profit Maximizing Trade Tips - ulpravda.ru
Oncolytics Biotech Moves to Extend Pelareorep Patent Runway Beyond 2044 - TipRanks
Oncolytics Biotech files patent application to extend pelareorep protection - Investing.com
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - Investing News Network
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics Biotech expands GI cancer advisory board with three experts By Investing.com - Investing.com Nigeria
Oncolytics Biotech Adds Leading GI Oncologists to Advisory Board as It Prepares Pivotal Pelareorep Trials - TipRanks
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris - Business Wire
Smart Oncology: 5 Stocks Chasing the $317B Prize - The Globe and Mail
What drives Oncolytics Biotech Inc stock priceStock Rotation Strategies & Big Profit Small Investment - earlytimes.in
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Shares Down 1.5%Here's Why - MarketBeat
Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting - ACCESS Newswire
Revenue per share of Oncolytics Biotech Inc. – NASDAQ:ONCY - TradingView — Track All Markets
What hedge fund activity signals for Oncolytics Biotech Inc. stockWeekly Profit Recap & Technical Pattern Based Signals - Улправда
Why Oncolytics Biotech Inc. stock is recommended by analystsMarket Growth Report & Real-Time Buy Signal Notifications - Улправда
Published on: 2025-12-20 04:27:06 - Улправда
Will Oncolytics Biotech Inc. stock sustain high P E ratiosMarket Activity Summary & Consistent Return Strategy Ideas - DonanımHaber
Is Oncolytics Biotech Inc. stock trading near support levelsCPI Data & AI Enhanced Trading Signals - DonanımHaber
What analyst consensus says on Oncolytics Biotech Inc. stockJuly 2025 Retail & Reliable Entry Point Trade Alerts - Улправда
Published on: 2025-12-18 16:49:38 - Улправда
Lake Street Remains a Buy on Oncolytics Biotech (ONCY) - The Globe and Mail
[6-K] ONCOLYTICS BIOTECH INC Current Report (Foreign Issuer) | ONCY SEC FilingForm 6-K - Stock Titan
Oncolytics eyes controlled study for pelareorep in colorectal cancer - The Pharma Letter
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer - BioSpace
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Cantech Letter
Oncolytics Says Pelareorep Shows 33% Response Rate in Colorectal Cancer Patients; Shares Rise - marketscreener.com
Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards - GlobeNewswire
Oncolytics rises on additional data for pelareorep in colorectal cancer - Seeking Alpha
Oncolytics reports 33% response rate in hard-to-treat colorectal cancer - Investing.com India
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):